IN VITRO ANTICANCER ACTIVITY OF HISTATIN-1 COMBINATION WITH CISPLATIN IN HEAD AND NECK CANCER CELL LINES
DOI:
https://doi.org/10.15407/exp-oncology.2024.02.101Keywords:
AMPs, anticancer activity, combination therapy, histatin, HNSCCAbstract
Background. Chemotherapy of head and neck squamous cell carcinoma (HNSCC) is associated with significant side effects. Antimicrobial peptides (AMPs), which are naturally occurring defense molecules like defensin-1 and LL-37 found in human secretions, have demonstrated potential in prompting tumor cell apoptosis and enhancing the effect of chemotherapeutic agents. However, the anticancer potential of histatin has not yet been thoroughly examined. The aim of the study was to explore the anticancer activity of histatin, an AMP present in human saliva and used alone or in combination with cisplatin in HNSCC cell lines. Materials and Methods. The gene expression of histatin was evaluated in the HSC4 and SCC25 cell lines by qRT-PCR. Cell proliferation was investigated at different concentrations of histatin peptide (His-1), cisplatin, and their combination using an MTT assay. Results. SCC25 cells expressed both HTN1 (histatin-1) and HTN3 (histatin-3), whereas the HSC4 cell line expressed only HTN1. The combination of exogenous His-1 and cisplatin demonstrated a synergistic anti-proliferative effect against the HNSCC cell lines in a dosedependent manner. Conclusions. The combination of low-dose cisplatin and histatin inhibits HNSCC cell proliferation. His-1 sensitizes tumor cells to the cytotoxic effects of cisplatin potentially allowing for a reduction in its effective concentration.
References
Sindhu SK, Bauman JE. Current concepts in chemotherapy for head and neck cancer. Oral Maxillofac Surg Clin North Am. 2019;31:145-154. https://doi.org/ 10.1016/j.coms.2018.09.003
Tornesello AL, Borrelli A, Buonaguro L, et al. Antimicrobial peptides as anticancer agents: functional properties and biological activities. Molecules. 2020;25:2850. https://doi.org/10.3390/molecules25122850
Andreadis C, Vahtsevanos K, Sidiras T, et al. 5-Fluorouracil and cisplatin in the treatment of advanced oral cancer.
Oral Oncol. 2003;39:380-385. https://doi.org/10.1016/s1368-8375(02)00141-0
Shah FD BR, Vajaria BN, Patel KR, et al. A review on salivary genomics and proteomics biomarkers in oral cancer.
Indian J Clin Biochem. 2011:26(24):326-334. https://doi.org/10.1007/s12291-011-0149-8
Mansoori B, Mohammadi A, Davudian S, et al. The different mechanisms of cancer drug resistance: a brief review.
Adv Pharm Bull. 2017;7:339-348. https://doi.org/10.15171/apb.2017.041
Zhang F, Wang Y, Wang ZQ, et al. Effi acy and safety of cisplatin-based versus nedaplatin-based regimens for the treat- ment of metastatic/recurrent and advanced esophageal squamous cell carcinoma: a systematic review and meta- analysis. Dis Esophagus. 2017;30:1-8. https://doi.org/10.1111/dote.12490
Housman G, Byler S, Heerboth S, et al. Drug resistance in cancer: an overview. Cancers (Basel). 2014;6:1769-1792. https://doi.org/10.3390/cancers6031769
Chen X, Zou X, Qi G, et al. Roles and mechanisms of human cathelicidin LL-37 in cancer. Cell Physiol Biochem. 2018;47:1060-1073. https://doi.org/10.1159/000490183
Shah D, Ali M, Pasha Z, et al. Histatin-1 expression in human lacrimal epithelium. PLoS One. 2016;11:e0148018. https://doi.org/10.1371/journal.pone.0148018
Oudhoff MJ, Bolscher JG, Nazmi K, et al. Histatins are the major wound-closure stimulating factors in human saliva as identified in a cell culture assay. FASEB J. 2008;22:3805-3812. https://doi.org/10.1096/fj.08-112003
Sun W, Ma D, Bolscher JGM, et al. Human salivary histatin-1 promotes osteogenic cell spreading on both bio- inert substrates and titanium SLA surfaces. Front Bioeng Biotechnol. 2020;8:584410. https://doi.org/10.3389/ fbioe.2020.584410
Zhu J, Luther PW, Leng Q, et al. Synthetic histidine-rich peptides inhibit Candida species and other fungi in vitro: role of endocytosis and treatment implications. Antimicrob Agents Chemother. 2006;50:2797-2805. https://doi. org/10.1128/aac.00411-06
Torres P, Diaz J, Arce M, et al. The salivary peptide histatin-1 promotes endothelial cell adhesion, migration, and angio- genesis. FASEB J. 2017;31:4946-4958. https://doi.org/ 10.1096/fj.201700085R
Chernov AN, Tsapieva A, Alaverdian DA, et al. In vitro evaluation of the cytotoxic effect of Streptococcus pyogenes strains, protegrin PG-1, cathelicidin LL-37, nerve growth factor and chemotherapy on the C6 glioma cell line. Mole- cules. 2022;27:569. https://doi.org/10.3390/molecules27020569
Cheah YH, Liu CY, Yip BS, et al. Strategy to enhance anticancer activity and induced immunogenic cell death of antimicrobial peptides by using non-nature amino acid substitutions. Biomedicines. 2022;10:1097. https://doi. org/10.3390/biomedicines10051097
Khurshid Z, Naseem M, Sheikh Z, et al. Oral antimicrobial peptides: Types and role in the oral cavity. Saudi Pharm J. 2016;24:515-524. https://doi.org/10.1016/j.jsps.2015.02.015
Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364-378. https://doi.org/10.1016/j.ejphar.2014.07.025
Wodlej C, Riedl S, Rinner B, et al. Interaction of two antitumor peptides with membrane lipids - Influence of phospha- tidylserine and cholesterol on specificity for melanoma cells. PLoS One. 2019;14:e0211187. https://doi.org/10.1371/ journal.pone.0211187
Wongpanuwich W, Yodsanga S, Chaisuparat R, et al. Association between PD-L1 and histatin1, 3 expression in ad- vanced head and neck squamous cell carcinoma. Anticancer Res. 2022;42:2689-2699. https://doi.org/10.21873/anti- canres.15747
Vierthaler M, Rodrigues PC, Sundquist E, et al. Fluctuating role of antimicrobial peptide hCAP18/LL-37 in oral tongue dysplasia and carcinoma. Oncol Rep. 2020;44:325-338. https://doi.org/10.3892/or.2020.7609
Chen X, Ji S, Si J, et al. Human cathelicidin antimicrobial peptide suppresses proliferation, migration and inva- sion of oral carcinoma HSC-3 cells via a novel mechanism involving caspase-3 mediated apoptosis. Mol Med Rep. 2020;22:5243-5250. https://doi.org/ 10.3892/mmr.2020.11629
Jafari A, Babajani A, Sarrami Forooshani R, et al. Clinical applications and anticancer effects of antimicrobial pep- tides: from bench to bedside. Front Oncol. 2022;12:819563. https://doi.org/ 10.3389/fonc.2022.819563
Patil SM, Kunda NK. Nisin ZP, An antimicrobial peptide, induces cell death and inhibits non-small cell lung cancer (NSCLC) progression in vitro in 2D and 3D cell culture. Pharm Res. 2022;39:2859-2870. https://doi.org/10.1007/ s11095-022-03220-2
Dennison RS, Whittaker M, Harris F, et al. Anticancer alpha-helical peptides and structure/function relationships underpinning their interactions with tumour cell membranes. Curr Protein Pept Sci. 2006;7:487-499. https://doi. org/10.2174/138920306779025611
Huang Y, Feng Q, Yan Q, et al. Alpha-helical cationic anticancer peptides: a promising candidate for novel anticancer drugs. Mini Rev Med Chem. 2015;15:73-81. https://doi.org/ 10.2174/1389557514666141107120954
Ventura TMO, Ribeiro NR, Taira EA, et al. Radiotherapy changes the salivary proteome in head and neck cancer patients: evaluation before, during, and after treatment. Clin Oral Investig. 2022;26:225-258. https://doi.org/10.1007/ s00784-021-03995-5
Den Hertog AL, van Marle J, van Veen HA, et al. Candidacidal effects of two antimicrobial peptides: histatin 5 causes small membrane defects, but LL-37 causes massive disruption of the cell membrane. Biochem J. 2005;388:689-695. https://doi.org/10.1042/bj20042099
Winter J, Pantelis A, Reich R, et al. Human beta-defensin-1, -2, and -3 exhibit opposite effects on oral squamous cell carcinoma cell proliferation. Cancer Invest. 2011;29:196-201. https://doi.org/10.3109/07357907.2010.543210
Lu F, Zhu Y, Zhang G, et al. Renovation as innovation: repurposing human antibacterial peptide LL-37 for cancer therapy. Front Pharmacol. 2022;13:944147. https://doi.org/10.3389/fphar.2022.944147
Chuang C-M, Monie A, Wu A, et al. Treatment with LL-37 peptide enhances antitumor effects induced by CpG oligo- deoxynucleotides against ovarian cancer. Human Gene Ther. 2009;20:303-313. https://doi.org/10.1089/hum.2008.124
Porter RJ, Murray GI, Alnabulsi A, et al. Colonic epithelial cathelicidin (LL-37) expression intensity is associated with progression of colorectal cancer and presence of CD8(+) T cell infiltrate. J Pathol Clin Res. 2021;7:495-506. https://doi.org/10.1002/cjp2.222
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
